MedPath

In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency

Not Applicable
Completed
Conditions
Chronic Obstructive Airway Disease
Airflow Obstruction, Chronic
Pulmonary Disease, Chronic Obstructive
Chronic Obstructive Lung Disease
Interventions
Device: Standard Oxygen Cannula
Device: NIOV System
Registration Number
NCT01347931
Lead Sponsor
Breathe Technologies, Inc.
Brief Summary

The Breathe NIOV™ System will reduce the work of breathing in subjects with chronic respiratory insufficiency who require long-term oxygen therapy (LTOT). The Breathe system will accomplish this by providing oxygen under pressure and augmenting the subject's spontaneous tidal volumes. The combination of efficient oxygen delivery, assisted ventilation, and a comfortable low-profile device, will result in a mean improvement in perceived well-being and ability to perform ADLs, as measured by patient-reported outcome (PRO) instruments.

Detailed Description

This will be a prospective, open-label, crossover study in up to 12 stable subjects with chronic respiratory insufficiency who require LTOT. Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator system during selected activities of daily living. Subjects will participate in the study for up to 9 home visits, with Visits 1 and 2 each lasting for approximately 4 hours, and Visits 3-9 lasting approximately 1-2 hours each. Subjects may discontinue study participation at any time.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
30
Inclusion Criteria
  • Adult male and female subjects, 21-80 years of age
  • Diagnosis of chronic respiratory insufficiency including COPD and interstitial lung disease
  • Requires use of continuous nasal oxygen of at least 2 lpm
  • Reports limitation of activity due to fatigue or breathlessness
  • Fluent in written and spoken English language
  • Ability to be properly fitted with the Breathe nasal mask
  • Ability to tolerate and be appropriately titrated on the Breathe ventilator
  • Ability to communicate self-assessment of dyspnea, comfort, and fatigue
  • Ability and willingness to participate in the study including walking and other activities of daily living
  • Ability to provide written informed consent
Exclusion Criteria
  • Recent history of frequent or severe epistaxis
  • Symptoms of acute respiratory exacerbation within 48 hours of Study Day 1
  • Discharge from the hospital within 30 days of study enrollment
  • Subjects, who in the opinion of the Investigator, are not suitable candidates for enrollment or who are unlikely to be able to comply with trial requirements
  • Subjects with conditions that, in the Investigator's opinion, contraindicates study participation

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Standard Oxygen TherapyStandard Oxygen CannulaSupplemental oxygen using standard oxygen cannula connected to a portable oxygen cylinder.
NIOV SystemNIOV SystemNoninvasive ventilation and oxygen delivered via NIOV System oxygen using an open nasal interface. Connected to standard portable oxygen cylinder
Primary Outcome Measures
NameTimeMethod
Activity Endurance TimeMeasured during single day study visit

Time in minutes of sustained activity while using test treatments

Secondary Outcome Measures
NameTimeMethod
Borg Dyspnea ScoreMeasured during activity testing in a single day study visit

Borg Dyspnea score is measured using a 11-point visual analog scale. The lower the score on the scale, the less breathlessness patient experiences. The score ranges from:

0 = No breathlessness at all, representing better outcome 10 = Maximum, representing worse outcome

Arterial Oxygen SaturationMeasured during activity testing in a single day study visit

O2 saturation measured by pulse oximetry

Trial Locations

Locations (1)

Allegheny General Hospital

🇺🇸

Pittsburgh, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath